Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
7.1M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
192K
-
Shares change
-
-6.14K
-
Total reported value, excl. options
-
$230K
-
Value change
-
-$6.16K
-
Number of buys
-
2
-
Number of sells
-
-2
-
Price
-
$1.17
Significant Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) as of Q3 2024
7 filings reported holding DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value as of Q3 2024.
BRIGHT MINDS BIOSCIENCES INC. - Common Stock, no par value (DRUG) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 192K shares
of 7.1M outstanding shares and own 2.7% of the company stock.
Largest 7 shareholders include AdvisorShares Investments LLC (182K shares), NATIONAL BANK OF CANADA /FI/ (4.96K shares), UBS Group AG (3.41K shares), Royal Bank of Canada (660 shares), Aspire Private Capital, LLC (100 shares), BlackRock, Inc. (1 shares), and JANE STREET GROUP, LLC (0 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.